Study Overview: This study looks at a treatment called lurbinectedin for young people with Ewing sarcoma, a type of cancer affecting bones or soft tissue. The study has two parts. Phase 1 checks if the treatment is safe and how the body processes it in children with solid tumors. Phase 2 tests if it works well and is safe in children and young adults with Ewing sarcoma.
Key Points:
- This study involves two phases and participants must be between 2 and 30 years old.
- Participants must have been previously treated for their cancer and meet various health criteria.
- Male and female participants must follow specific guidelines to prevent pregnancy during the study.
Important Details: Those who join the study will need to meet specific health and age requirements. They will not be eligible if they have certain medical conditions or have had specific treatments before. Participants cannot have certain infections like Hepatitis B or HIV. The study requires commitment, and participants or guardians must be able to attend scheduled visits and follow study rules.